Yasui et al., 2019 also found that a high AR mRNA-expressing group tended to have a longer recurrence-free survival, and Katleba et al., 2021 found a low molecular weight variant of the androgen receptor in most bladder cancer malignancies, missing the ligand binding domain [67,118]. This evidence concerns the gene AR and urinary bladder cancer.